Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,223.80
Bid: 1,224.00
Ask: 1,224.20
Change: -0.40 (-0.03%)
Spread: 0.20 (0.02%)
Open: 1,212.40
High: 1,226.80
Low: 1,210.80
Yest. Close: 1,224.20
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

GSK to sell down Aspen Pharma stake

GlaxoSmithKline has revealed plans to sell 450m pounds of shares in Africa's largest drug company, Aspen Pharmaceutical. GSK said it wanted to offload around a third of its 19% stake in Johannesburg-listed Aspen, which is currently valued at 122bn rand, equivalent to £7.5bn. The 6% of sold shares

19 Nov 13 15:31

Global drug spending to surpass $1 trillion in 2014 -report

Nov 19 (Reuters) - Global spending on drugs will surpass $1 trillion next year and increase 3 to 6 percent annually over the next five years as both developed and developing nations spend more on medicine, according to a study released on Tuesday. Spending on expensive new specialty drugs f

19 Nov 13 13:53

UPDATE 1-U.S. Senate backs bill to regulate big drug compounders

WASHINGTON, Nov 18 (Reuters) - The U.S. Senate on Monday approved a bill designed to prevent the type of quality control problems that lead last year to a deadly outbreak of fungal meningitis that was traced to a tainted pharmaceutical mixed by a Massachusetts pharmacy. The bill, known as t

18 Nov 13 19:55

DIRECTOR DEALINGS: GlaxoSmithKline Manager Sells Shares After Exercising Options

18 Nov 13 18:54

GSK awarded European marketing authorisation for asthma and COPD treatment

Pharmaceutical giant GlaxoSmithKline (GSK) has received European marketing authorisation for Relvar Ellipta, a treatment for asthma and Chronic Obstructive Pulmonary Disease (COPD), which is now licensed across 31 European countries. Darrell Baker, the Head of GSK Global Respiratory Franchise, sai

18 Nov 13 15:13

GSK's asthma drug Relvar approved in Europe

LONDON, Nov 18 (Reuters) - GlaxoSmithKline and Theravance's new inhaled lung drug Relvar has been approved in Europe to treat both asthma and chronic obstructive pulmonary disease (COPD), confirming an endorsement from regulators in September. The medicine, which is inhaled through a palm-s

18 Nov 13 13:45

GlaxoSmithKline Granted Europe Marketing Authorisation For Relvar Ellipta

18 Nov 13 13:31

DIRECTOR DEALINGS: GlaxoSmithKline Executives Allocated Additional American Depositary Shares

15 Nov 13 17:34

Last-line antibiotics losing ability to kill superbugs in EU

* ECDC survey shows rise in carbapenem resistance * Problem most acute in southern Europe * Health experts urge prudent drug use, more research By Ben Hirschler LONDON, Nov 15 (Reuters) - Europe faces a growing threat from superbugs that are resistant to a powerful, last-r

15 Nov 13 13:04

CORRECTED-Merck invests $107 million in China drug plant

(Corrects company name and RIC to Merck KGaA in para 1, deletes reference to Merck in para 6) * China market could by world's second-biggest by 2016 * Healthcare spending forecast to hit $1 trillion by 2020 * Major drug companies investigated on pricing, corruption * Inter

15 Nov 13 12:32

Merck invests $107 million in China drug plant

* China market could by world's second-biggest by 2016 * Healthcare spending forecast to hit $1 trillion by 2020 * Major drug companies investigated on pricing, corruption * International firms can't afford to stay out of China-lawyer SHANGHAI, Nov 15 (Reuters) - German dr

15 Nov 13 09:46

UPDATE 2-Sarepta shares plunge 60 pct after FDA questions drug trial

* FDA questions drug trial design, says approval application premature * FDA suggests company may need to do larger trial * Analysts say there's almost no chance of an early approval * At least three brokerages downgrade stock * Stock drop wipes off $750 mln of Sarepta's m

12 Nov 13 18:15

DIRECTOR DEALINGS: Glaxo Executives Acquire Shares

12 Nov 13 16:42

UPDATE 1-FDA raises doubts about trial of Sarepta lead drug, shares plunge

(Adds details, background; updates stock movement) Nov 12 (Reuters) - Sarepta Therapeutics Inc said the U.S. Food and Drug Administration has expressed doubts that the design and goals for the trial of its lead drug were sufficient to support marketing approval, sending its shares down near

12 Nov 13 14:51

Broker tips: RBS, Vodafone, GlaxoSmithKline

Analysts at Goldman Sachs have a positive view on the strategy outlined by Royal Bank of Scotland alongside its third-quarter results. However, the group's new target for common Tier-1 equity, of over 12% versus over 10% before, means that there is now reduced upside potential in RBS shares, "towar

12 Nov 13 12:56

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.